Meeting
2023 ASCO Genitourinary Cancers Symposium
Evaluating technical feasibility of a urine cell-free DNA (cfDNA) NGS assay for identifying biomarkers in bladder cancer.
Authors
Il-Jin Kim
Predicine, Inc., Hayward, CA
Il-Jin Kim , Michelle Quiroz , Zhixin Zhao , Wei Mo , Tiantian Zheng , Amy Wang , Usha Singh , Neil Beeharry , Denis Smirnov , Songbai Wang , Renee Tate , Tom Zhang , Fang Liu , Seema Hanumanthe , Binggang Xiang , Shujun Luo , Alexander Kuklin , Ralph M. Wirtz , Pan Du , Shidong Jia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 565)
DOI
10.1200/JCO.2023.41.6_suppl.565
Abstract #
565
Poster Bd #
N8
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Diagnosis of prostate cancer and benign prostatic hyperplasia based on urinary cell-free DNA methylation characteristics.
First Author: Jindan Luo
Poster
2023 ASCO Annual Meeting
Evaluating the use of circulating tumor DNA (ctDNA) in patients with urothelial cancer in the context of FGFR-targeted therapy.
First Author: Elena Schönlau
Poster
2023 ASCO Annual Meeting
An in-progress phase 2 window of opportunity (WOO) trial of targeted therapy with erdafitinib for patients with recurrent FGFR3-altered non–muscle-invasive bladder cancer (NMIBC).
First Author: Neeta DSouza
Poster
2023 ASCO Genitourinary Cancers Symposium
Survey of keratin 17 (K17) expression in different urothelial malignancies.
First Author: Thorsten Ecke